Abstract OBJECTIVE: To examined serum B-type natriuretic peptide (BNP) levels and BNP expression of protein and mRNA in the right ventricular myocardium in juvenile rats with right heart failure (RHF) and the effects of β-adrenergic receptor blocker carvedilol on serum and myocardial BNP levels in order to investigate the role of BNP in the diagnosis and treatment of RHF. METHODS: Fifty-one four-week-old Sprague-Dawley rats were randomly assigned to 5 groups: RHF 1, RHF 2, carvedilol-treated RHF, control 1 and control 2. RHF was developed 4 weeks after an intraperitoneal injection of monocrotaline in the RHF 1, RHF 2 and carvedilol-treated RHF groups. The rats in the RHF 1 and the control 1 groups were sacrificed after the RHF event for observing pathological changes in the myocardium. After the RHF event, the carvedilol-treated group was given intragastric administration of carvedilol (3.5 mg/kg/d) for 2 weeks. The RHF 2 and the control 2 groups were given distilled water of equal dose instead. The rats were sacrificed 2 weeks after carvedilol or distilled water administration. Serum BNP levels were measured using ELISA. BNP protein and mRNA expression in the right ventricular myocardium were measured by immunohistochemistry and RT-PCR, respectively. Haemodynamics and some physiological indexes were measured. RESULTS: Serum BNP levels and BNP protein and mRNA expression in the right ventricular myocardium were significantly higher in the RHF 1 group than those in the control 1 group (P<0.01). Serum BNP levels and BNP protein and mRNA expression in the right ventricular myocardium increased more significantly in the RHF 2 group. There was a positive correlation between serum BNP levels and myocardial BNP protein expression in the RHF group (r=0.698, P<0.01). Serum BNP levels and BNP protein and mRNA expression in the carvedilol-treated RHF group were significantly reduced when compared with the RHF 2 group (P<0.05). Carvedilol treatment also resulted in improved hemodynamics and relieved right ventricular hypertrophy. CONCLUSIONS: BNP may serve an index for the diagnosis of RHF and the evaluation of severity in children with RHF. Carvedilol shows protections against RHF caused by pressure load.[Chin J Contemp Pediatr, 2009, 11 (7):571-576]
AN Jin-Dou,LIANG Fang,FENG Song. B-type natriuretic peptide (BNP) levels and the effects of carvedilol on BNP levels in juvenile rats with right heart failure[J]. 中国当代儿科杂志, 2009, 11(07): 571-576.
AN Jin-Dou,LIANG Fang,FENG Song. B-type natriuretic peptide (BNP) levels and the effects of carvedilol on BNP levels in juvenile rats with right heart failure[J]. CJCP, 2009, 11(07): 571-576.
[1]Krüger S, Graf J, Merx MW, Koch KC, Kunz D, Hanrath P, et al. Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism[J]. Am Heart J, 2004, 147(1):60-65.
[2]Qvigstad E, Sjaastad I, Bokenes J, Schiander I, Solberg L, Sejersted OM, et al. Carvedilol blockade of alpha1-and beta-adrenoceptor induced inotropic responses in rats with congestive heart failure[J].Eur J Pharmacol, 2005, 516(1):51-59.
[3]Dalla Libera L, Ravara B, Angelini A, Rossini K, Sandri M, Thiene G, et al. Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure[J]. Circulation, 2001, 103(17):2195-2200.
[4]Campian ME, Hardziyenka M, Michel MC, Tan HL. How valid are animal models to evaluate treatments for pulmonary hypertension?[J]. Naunyn Schmiedebergs Arch Pharmacol, 2006, 373(6):391-400.
[6]Liang YJ, Lai LP, Wang BW, Juang SJ, Chang CM, Leu JG, et al. Mechanical stress enhances serotonin 2B receptor modulating brain natriuretic peptide through nuclear factor-kappaB in cardiomyocytes[J]. Cardiovasc Res, 2006, 72(2):303-312.
[7]Wang J, Marui A, Ikeda T, Komeda M. Partial left ventricular unloading reverses contractile dysfunction and helps recover gene expressions in failing rat hearts[J]. Interact Cardiovasc Thorac Surg, 2008, 7(1):27-31.
[8]Pruszczyk P. N-terminal Pro-brain natriuretic peptide as an indicator of right ventricular dysfunction[J]. J Card Fail, 2005, 11(5 Suppl):S65-69.
[9]Usui S, Yao A, Hatano M, Kohmoto O, Takahashi T, Nagai R, et al. Upregulated neurohumoral factors are associated with left ventricular remodeling and poor prognosis in rats with monocrotaline-induced pulmonary arterial hypertension[J]. Circ J, 2006, 70(9):1208-1208.
[10]Mariano-Goulart D, Eberlé MC, Boudousq V, Hejazi-Moughari A, Piot C, et al. Major increase in brain natriuretic peptide indicates right ventricular systolic dysfunction in patients with heart failure[J]. Eur J Heart Fail, 2003, 5(4):481-488.
[11]Costello JM, Backer CL, Checchia PA, Mavroudis C, Seipelt RG, Goodman DM. Alterations in the natriuretic hormone system related to cardiopulmonary bypass in infants with congestive heart failure[J]. Pediatr Cardiol, 2004, 25(4):347-353.
[12]Nagaya N, Ando M, Oya H, Ohkita Y, Kyotani S, Sakamaki F, et al. Plasma brain natriuretic peptide as a non-invasive marker for efficacy of pulmonary thromboendarterectomy[J]. Ann Thorac Surg, 2002, 74(1):180-184.
[13]Cauliez B, Berthe MC, Lavoinne A. Brain natriuretic peptide: physiological, biological and clinical aspects[J]. Ann Biol Clin (Paris), 2005, 63(1):15-25.
[14]Heidrich FM, Zhang K, Estrada M, Huang Y, Giordano FJ, Ehrlich BE. Chromogranin B regulates calcium signaling, nuclear factor kappaB activity, and brain natriuretic peptide production in cardiomyocytes[J]. Circ Res, 2008, 102(10):1230-1238.
[15]Tota B, Angelone T, Mazza R, Cerra MC. The chromogranin A-derived vasostatins: new players in the endocrine heart.Curr Med Chem[J]. 2008, 15 (14):1444-1451.
[16]Langenickel T, Pagel I, Hohnel K, Dietz R, Willenbrock R. Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure[J]. Am J Physiol Heart Circ Physiol, 2000, 278(5):H1500-1506.
[17]Guerra MS, Roncon-Albuquerque R Jr, Lourenco AP, Falcao-Pires I, Cibrao-Coutinho P, Leite-Moreira AF. Remote myocardium gene expression after 30 and 120 min of ischaemia in the rat[J]. Exp Physiol, 2006, 91(2):473-480.
[18]Frantz RP, Olson LJ, Grill D, Moualla SK, Nelson SM, Nobrega TP, et al. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure[J]. Am Heart J, 2005, 149(3):541-547.
[19]Shyu KG, Liou JY, Wang BW, Fang WJ, Chang H. Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor1alpha and vascular endothelial growth factor in pressure-overloaded rat heart[J]. J Biomed Sci, 2005, 12(2):409-420.
[20]Qvigstad E, Sjaastad I, B-kenes J, Schiander I, Solberg L, Sejersted OM, et al. Carvedilol blockade of alpha1-and beta-adrenoceptor induced inotropic responses in rats with congestive heart failure[J].Eur J Pharmacol, 2005, 516(1):51-59.